omniture
logo
Search
FORESEE PHARMACEUTICALS CO. LTD.
Media Room

Latest News

rss

Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease

TAIPEI, Oct. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced t...

2023-10-30 15:18 1262

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023

TAIPEI, July 25, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced t...

2023-07-25 15:19 1849

Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development

TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), an...

2023-04-17 16:50 1654

Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement

TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTa...

2022-02-23 23:00 2133

Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization

TAIPEI, May 26, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced toda...

2021-05-27 11:33 2329

Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

TAIPEIMarch 27, 2021 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), toda...

2021-03-28 11:04 2399

Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States

TAIPEI, March 4, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced toda...

2021-03-04 23:00 2914

Foresee Pharmaceuticals Announces Completion of US$47 Million Financing

TAIPEI, Dec. 24, 2020 /PRNewswire/ -- Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announce...

2020-12-24 18:00 10498

Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China

TAIPEI, Nov. 17, 2020 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced toda...

2020-11-17 17:51 1966

Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA

TAIPEI, Oct. 8, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") annou...

2020-10-09 06:39 2030

Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg

TAIPEI, Taiwan, July 27, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Forese...

2020-07-28 12:34 1971

Foresee Pharmaceuticals and Accord Healthcare Announce MAA Submission for Camcevi(R) 42mg

TAIPEI, March 27, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") and...

2020-03-27 19:53 3897